Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–2 of 2 results
Advanced filters: Author: "Volker Brinkmann" Clear advanced filters

  • In addition to their phagocytic activity, neutrophils can also kill microorganisms by the release of neutrophil extracellular traps or NETs — fibrous extracellular structures that are composed of chromatin with proteins from the neutrophilic granules attached. Brinkmann and Zychlinsky provide an overview of the structure, function and generation of NETs.

    • Volker Brinkmann
    • Arturo Zychlinsky
    Reviews
    Nature Reviews Microbiology
    Volume: 5, P: 577-582

  • In September 2010, fingolimod (FTY720/Gilenya; Novartis) became the first oral disease-modifying therapy to be approved by the US Food and Drug Administration for relapsing–remitting multiple sclerosis. Brinkmann and colleagues describe its discovery and development, and how elucidation of its effects on sphingosine 1-phosphate receptors has improved the understanding of the biology of these receptors.

    • Volker Brinkmann
    • Andreas Billich
    • Pascale Burtin
    Reviews
    Nature Reviews Drug Discovery
    Volume: 9, P: 883-897